肿瘤浸润淋巴细胞(TILs)免疫疗法及其在肺癌治疗中应用的研究进展  

Research progress of tumor-infiltrating lymphocytes(TILs)immunotherapy and its application in lung cancer treatment

作　　者：宫昕宇 李强[1] 李川 卫佳尧 杨泽峰 范玉杰 GONG Xinyu;LI Qiang;LI Chuan;WEI Jiayao;YANG Zefeng;FAN Yujie(Shanxi Medicine University Second Hospital,Shanxi Taiyuan 030000,China)

机构地区：[1]山西医科大学第二医院,山西太原030000

出　　处：《现代肿瘤医学》2025年第4期712-718,共7页Journal of Modern Oncology

摘　　要：肺癌是全球癌症相关死亡的主要原因,尽管过去在肺癌治疗方面取得了许多进展,但对于那些不适合靶向治疗及免疫治疗或在一线治疗后出现进展的患者,目前尚缺乏有效的二线治疗方案。基于肿瘤浸润淋巴细胞(tumor-infiltrating lymphocytes,TILs)的过继性细胞疗法(adoptive cell therapy,ACT),是一种高度个性化的癌症免疫治疗方法,利用患者自身实体瘤微环境的免疫细胞杀死肿瘤细胞。该文综述TILs疗法的基本过程,讨论了当前在肺癌治疗过程中TILs方案的应用以及TILs疗法的局限性和未来发展方向,以期在肺癌治疗过程中获得更广泛的临床应用。Lung cancer is the leading cause of cancer-related death worldwide.Despite many advances in the treatment of lung cancer in the past,there is currently a lack of effective second-line treatment options for patients who are not candidates for targeted therapy and immunotherapy or who progress after first-line treatment.Adoptive cell therapy(ACT),based on tumor-infiltrating lymphocytes(TILs),is a highly personalized approach to cancer immunotherapy.Tumor cells are killed using immune cells from the patient's own solid tumor microenvironment.This article reviews the basic process of TILs therapy,discusses the current application of TILs in the treatment of lung cancer,as well as the limitations and future development direction of TILs therapy,in order to obtain more extensive clinical application in the treatment of lung cancer.

关 键 词：肺癌 免疫治疗 肿瘤浸润淋巴细胞 过继性细胞疗法 

分 类 号：R734.2[医药卫生—肿瘤]